[{"id":"e6ac2588-b3b4-4351-aaa6-5c834e8a6d9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05489276","created_at":"2022-08-05T13:57:08.295Z","updated_at":"2024-07-02T16:36:06.008Z","phase":"Phase 1","brief_title":"Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors","source_id_and_acronym":"NCT05489276","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB2825"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 10/01/2023","primary_completion_date":" 10/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-08-05"}]